2025
Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025 PMID: 40549581, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original ResearchWeight loss medicationsGlucagon-like peptide-1Weight lossGastroenterology providersGlucagon-like peptide-1 receptor agonistsPrescribed off-label medicationsPrescribing weight loss medicationsOff-label medicationsFDA-approved medicationsLiver transplant centersOff-label prescribingMedication prescription ratesReceptor agonistsCost/insurance coveragePrescription ratesLiver diseaseSide effectsTransplant centersPeptide-1Steatotic liver diseaseObesity educationBenefit patientsPatientsResmetiromMedicationTreatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.
Yi I, Gomes P, Hardy N, Rose B, Yu-Cherng C, Bialick S, Jonczak E, D'Amato G, Deshpande H, Carmagnani Pestana R, David B, Trent J, Campos F, Costa P. Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation. Journal Of Clinical Oncology 2025, 43: 11562-11562. DOI: 10.1200/jco.2025.43.16_suppl.11562.Peer-Reviewed Original ResearchDesmoid tumorsMedian TFSPatients treated with sorafenibMulti-institutional retrospective analysisPalmar-plantar erythrodysesthesia syndromeSide effectsDuration of sorafenib treatmentDuration of systemic therapyFuture treatmentPatient stopped therapyOutcomes of patientsLog-rank testKaplan-Meier curvesTime of discontinuationFactors associated with better outcomesMonths of durationProgression of diseaseDiscontinued sorafenibSorafenib discontinuationSorafenib useStable diseasePartial responseDiscontinued therapySystemic therapyTreatment discontinuationRole of high-dose interleukin-2 for melanoma in the age of cellular therapy
Buchbinder E, Lotze M, Margolin K, Amaria R, Sarnaik A, Seery V, Eroglu Z, Khaddour K, Warner A, Kluger H, Sznol M, Atkins M, Mcdermott D, Silk A. Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. Journal For ImmunoTherapy Of Cancer 2025, 13: e011119. PMID: 40447314, PMCID: PMC12128428, DOI: 10.1136/jitc-2024-011119.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesTIL infusionInterleukin-2Cellular therapyHigh-dose bolus IL-2High-dose interleukin-2Renal cell carcinoma patientsBolus interleukin-2Cytokine-related toxicitiesExcellent organ functionIL-2 monotherapyIL-2 toxicityLife-threatening side effectsPartial tumor regressionCell carcinoma patientsInterleukin-2 dosesT cell productionTreatment of patientsNational Cancer InstituteAdvanced melanomaTumor regressionCarcinoma patientsAdjunctive therapyInpatient administrationSide effectsOne-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.
Dholaria H, Tsetlina V, Simpson S, Gillies E, Eswaran N, Rodriguez-Galindo C, Schultz K, Chen K, Wu C, Krasin M, Roemer T, Christiansen H, Piao J, Laetsch T, Pashankar F, Kontny U, Gartrell R. One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma. Clinical Cancer Research 2025, of1-of9. PMID: 40445588, DOI: 10.1158/1078-0432.ccr-24-3546.Peer-Reviewed Original ResearchGerman Society of Pediatric Oncology and HematologyChildren's Oncology GroupNasopharyngeal carcinomaClinical trialsAnti-PD-1 therapyRadiation doseDecreased radiation dosePediatric clinical trialsSevere side effectsConcomitant chemotherapyAdjuvant immunotherapyInduction chemotherapyOncology GroupRelated toxicityTreated patientsExcellent survivalSide effectsChemotherapyLate effectsLong-term effectsImmunotherapyCarcinomaClinical priorityDoseResponse-adaptiveDelandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus
Oskoui M, Caller T, Parsons J, Servais L, Butterfield R, Bharadwaj J, Rose S, Tolchin B, Puskala Hamel K, Silsbee H, Dowling J. Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus. Neurology 2025, 104: e213604. PMID: 40367405, DOI: 10.1212/wnl.0000000000213604.Peer-Reviewed Original ResearchConceptsDuchenne muscular dystrophyFood and Drug AdministrationClinical trialsImmune-related side effectsMuscular dystrophyFood and Drug Administration approvalFunctional motor outcomePhase 3 clinical trialsTreatment groupsNorth Star Ambulatory Assessment scoresUS Food and Drug AdministrationMotor outcomeClinical trial dataRisk of biasClass I studiesGene therapyTreated patientsAmerican Academy of NeurologyLiver toxicityPrimary outcomeLiver injurySide effectsDrug AdministrationSafety outcomesDose exposure4-Anilinoquinolinylchalcone derivatives mediate antifibrotic effects through ERK/MRTF—a signaling pathway crosstalk
Selvam P, Tseng C, Wang C, Sun Y, Chen Y, Kao Y, Dahms H, Cheng C. 4-Anilinoquinolinylchalcone derivatives mediate antifibrotic effects through ERK/MRTF—a signaling pathway crosstalk. Environmental Science And Pollution Research 2025, 32: 11685-11696. PMID: 40234319, DOI: 10.1007/s11356-025-36382-8.Peer-Reviewed Original ResearchConceptsSide effectsAbnormal liver functionAnti-fibrosisSevere side effectsGroup of drugsAnti-inflammatory responseHuman immune systemSkin rashGenitourinary cancersMechanism of actionAntifibrotic effectsBreast cancerScreened 6Immunomodulatory qualitiesLiver functionPharmacological profileImmune systemSignaling pathwaySignaling pathway crosstalkQuinolone analoguesCancerAnti-cancerDerivativesBleedingRashBiologic Agents in Idiopathic Hypereosinophilic Syndrome
Papaioannou O, Sampsonas F, Tsiri P, Sotiropoulou V, Christopoulos I, Komninos D, Tzouvelekis A. Biologic Agents in Idiopathic Hypereosinophilic Syndrome. Pharmaceuticals 2025, 18: 543. PMID: 40283978, PMCID: PMC12030681, DOI: 10.3390/ph18040543.Peer-Reviewed Original ResearchIdiopathic hypereosinophilic syndromeHypereosinophilic syndromeDiagnosis of idiopathic hypereosinophilic syndromeBiological agentsToxicities of immunosuppressive agentsHeterogeneous group of rare disordersGroup of rare disordersDrug-related side effectsInitiation of biological agentsMethods:</b> PatientsTreated with mepolizumabEosinophilic pleural effusionValue of eosinophilsEyelid angioedemaOral corticosteroidsImmunosuppressive agentsPleural effusionConcomitant asthmaRare disordersSide effectsCardiac arrhythmiasAsthma flaresPatientsDiagnostic approachFunctional improvementSteroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
Richard E, Stephenson J, Desai N, Willey V, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng C, Oberprieler N. Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). Pragmatic And Observational Research 2025, 16: 121-127. PMID: 40196209, PMCID: PMC11974567, DOI: 10.2147/por.s489802.Peer-Reviewed Original ResearchSteroidal mineralocorticoid receptor antagonistsSide effectsMineralocorticoid receptor antagonistsHealthcare provider recommendationReceptor antagonistPatient toleranceTreatment patternsPast usersTreatment optionsMale gynecomastiaEligible patientsProvider recommendationPharmacy claimsPatientsResearch DatabaseMedication effectsMedical claimsPatient surveyHealthcare providersChronic conditionsTreatmentPatient perspectiveProvider decision-making processesEfficacy of anal botulinum toxin injection in children with functional constipation
Patel D, Saikumar P, Jayaraman M, Desai C, Rosen J, Rodriguez L. Efficacy of anal botulinum toxin injection in children with functional constipation. Journal Of Pediatric Gastroenterology And Nutrition 2025, 80: 956-962. PMID: 40123476, DOI: 10.1002/jpn3.70040.Peer-Reviewed Original ResearchConceptsResponse to therapyBotulinum toxin injectionFunctional constipationMedical therapyBotulinum toxinGroup 2Group 1No factorsGroup 3Side effectsRefractory to medical therapyResults of anorectal manometryDevelopmental delayDevelopment of side effectsPediatric age groupFrequency of BMPresence of developmental delayDose of botulinum toxinMedian doseMedian followAnorectal manometryMedian ageMulticenter studyBM frequencyLaxative regimensEvaluating the safety profile of connectome-based repetitive transcranial magnetic stimulation
Tang S, Holle J, Gabrielsson E, Dadario N, Ryan M, Sholas M, Sughrue M, Teo C, Yeung J. Evaluating the safety profile of connectome-based repetitive transcranial magnetic stimulation. Acta Neuropsychiatrica 2025, 37: e61. PMID: 40116602, DOI: 10.1017/neu.2025.9.Peer-Reviewed Original ResearchA plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Garcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer H, Azab M, Savona M. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology 2025, 21: 929-941. PMID: 40051275, PMCID: PMC11938952, DOI: 10.1080/14796694.2025.2468578.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaAcute myeloid leukemiaIntravenous decitabineMyelodysplastic syndromeDEC-COral decitabineSide effectsRed blood cell transfusionPhase 3 clinical trialsMedian overall survivalTreatment-related deathsBlood cell transfusionDays of treatmentTransfusion independenceOverall survivalCell transfusionDecitabine groupMyelomonocytic leukemiaMyeloid leukemiaOral medicineDecitabineQuality of lifeReceiving treatmentTaking treatmentCedazuridineAcceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study
Chayama K, Ng C, Brohman I, Mansoor M, Small W, Philbin M, Collins A, McNeil R. Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study. PLOS ONE 2025, 20: e0319010. PMID: 40019916, PMCID: PMC11870339, DOI: 10.1371/journal.pone.0319010.Peer-Reviewed Original ResearchConceptsAdherence to antiretroviral therapyLong-acting antiretroviral therapyLA-ARTAntiretroviral therapySuboptimal adherence to antiretroviral therapyAdherence barriersProspective cohort studySuboptimal ART adherenceAdverse side effectsPill burdenTreatment optionsSubstance useCohort studyART adherenceTreatment advancesSide effectsTreatment changesPLHIVTreatment approachesTherapyCredible sources of informationPopulation-level benefitsDrugHIVSocial-structural inequitiesMoving Beyond Desensitization to Tolerance in Food Allergy
Flom J, Shreffler W, Perrett K. Moving Beyond Desensitization to Tolerance in Food Allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 741-744. PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protectionMisoprostol administration mimicking a febrile transfusion reaction
Yurtsever N, Snyder E. Misoprostol administration mimicking a febrile transfusion reaction. Transfusion 2025, 65: 643-646. PMID: 39907501, DOI: 10.1111/trf.18150.Peer-Reviewed Original ResearchConceptsFebrile nonhemolytic transfusion reactionsTransfusion reactionsBlood culturesSynthetic prostaglandin E1 analogueThermogenic effectAdministration of misoprostolProstaglandin E1 analogueRed cell transfusionTransfusion medicineFebrile transfusion reactionsNonhemolytic transfusion reactionsG1P0 femaleMisoprostol administrationCell transfusionE1 analogueChart reviewSerological workupCase reportDifferential diagnosisEnhance patient satisfactionMisoprostolTransfusionUterotonic propertiesSerological findingsSide effectsP-1415. Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic
Kerrigan D, Scott R, O’Rourke A, Galai N, Karver T, Davis W, Metzner A, Oglesby A, Moriarty P, Taggart T, Barrington C, Gomez H, Perez M, Donastorg Y. P-1415. Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic. Open Forum Infectious Diseases 2025, 12: ofae631.1590. PMCID: PMC11777370, DOI: 10.1093/ofid/ofae631.1590.Peer-Reviewed Original ResearchPre-exposure prophylaxisLong-actingFemale sex workersSocial determinantsCisgender womenSocial determinants of healthHIV diagnosis ratesDaily oral PrEPDeterminants of healthBlack cisgender womenLow pre-exposure prophylaxisCross-sectional surveyOral PrEPUnited StatesHIV disparitiesWhite cisgender womenHIV inequitiesSide effectsIncreased oddsDiagnosis rateHIVPrEP preferencesDominican RepublicPrEPSex workersAntidopaminergic medications in Huntington's disease
Tan A, Geva M, Goldberg Y, Schuring H, Sanson B, Rosser A, Raymond L, Reilmann R, Hayden M, Anderson K. Antidopaminergic medications in Huntington's disease. Journal Of Huntington's Disease 2025, 14: 16-29. PMID: 39973394, DOI: 10.1177/18796397241304312.Peer-Reviewed Original ResearchConceptsAntidopaminergic medicationsSymbol Digit Modalities TestHuntington's diseaseComposite Unified Huntington’s Disease Rating Scale,Unified Huntington's Disease Rating ScaleExtrapyramidal symptomsWord readingHuntington's Disease Rating ScaleVMAT2 inhibitorsBehavioral impairmentsBehavioral disordersCognitive dysfunctionCognitive functionRating ScaleADM useDisease Rating ScaleHD symptomsTotal Functional CapacityModal testingMotor disturbancesFunctional impairmentProgressive neurodegenerative disorderMounting body of evidenceSide effectsBody of evidenceAnti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV.
Corti F, Locri F, Plastino F, Perrotta P, Zsebo K, Ristori E, Yin X, Song E, André H, Simons M. Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV. Translational Vision Science & Technology 2025, 14: 10. PMID: 39792057, PMCID: PMC11730891, DOI: 10.1167/tvst.14.1.10.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationLaser-induced choroidal neovascularizationAnti-VEGF therapyTransendothelial electrical resistanceVEGF-A activityChoroidal neovascularizationIntravitreal injectionRetinal lesionsLong-term anti-VEGF therapyMurine laser-induced choroidal neovascularizationNeovascular age-related macular degenerationWet age-related macular degenerationAlteration of visual acuityIntravitreal anti-VEGF therapySide effectsLocal intravitreal injectionReduced edema formationSuppression of edemaRelated side effectsPermeability in vitroEndothelial cell junctionsNeovascular AMDVisual acuityAssessed in vitroMacular degenerationTau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss
Fu W, Chen M, Wang K, Chen Y, Cui Y, Xie Y, Lei Z, Hu W, Sun G, Huang G, He C, Fretz J, Hettinghouse A, Liu R, Cai X, Zhang M, Chen Y, Jiang N, He M, Wiznia D, Xu H, Chen Z, Chen L, Tang K, Zhou H, Liu C. Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Cell Research 2025, 35: 23-44. PMID: 39743632, PMCID: PMC11701132, DOI: 10.1038/s41422-024-01016-0.Peer-Reviewed Original ResearchConceptsGC-induced osteoporosisBone lossInflammatory arthritisAdverse effects of dexamethasoneGlucocorticoid-induced bone lossHigh-dose dexamethasoneEffect of dexamethasoneFDA-approved drug librarySynthetic GCTreat inflammatory arthritisImmunosuppressive drugsPrescribed anti-inflammatoryGC receptorCombinatorial administrationSide effectsLow affinityGlucocorticoidOsteoporosisDexamethasoneReceptorsAdverse effectsBinding receptorsAnti-inflammatoryDrug libraryTau deficiency
2024
Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction
Wirt J, Ferreira L, Jesus C, Woodward T, Oliva I, Xu Z, Crystal J, Pepin R, Silverman R, Hohmann A. Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 122: e2318833121. PMID: 39793055, PMCID: PMC11725897, DOI: 10.1073/pnas.2318833121.Peer-Reviewed Original ResearchConceptsComplete Freund's adjuvantInflammatory painMechanical hypersensitivityAntinociceptive efficacyGlutamate levelsInjection of complete Freund's adjuvantConditioned place preference assayPaclitaxel-induced mechanical hypersensitivitySpinal site of actionSide effectsEnhancement of GABAergic transmissionChemotherapeutic agent paclitaxelPaclitaxel-induced increaseCompared to morphineLumbar spinal cordIncreased endogenous GABA levelsReduced glutamate levelsNeuropathic nociceptionSite of actionGABAergic transmissionAnalgesic strategiesPathological painGABAergic inhibitionSpinal sitesAbuse liabilityPractice Advisory for Postoperative Pain Management of Thoracic Surgical Patients: Executive Summary: A Report From the Society of Cardiovascular Anesthesiologists
Makkad B, Heinke T, Sheriffdeen R, Meng M, Kachulis B, Grant M, Popescu W, Brodt J, Khatib D, Wu C, Kertai M, Bollen B. Practice Advisory for Postoperative Pain Management of Thoracic Surgical Patients: Executive Summary: A Report From the Society of Cardiovascular Anesthesiologists. Journal Of Cardiothoracic And Vascular Anesthesia 2024, 39: 880-888. PMID: 39864980, DOI: 10.1053/j.jvca.2024.12.003.Peer-Reviewed Original ResearchThoracic surgical patientsPostoperative pain managementPostoperative painPain controlSurgical populationSurgical patientsOpioid-related side effectsRisk of respiratory complicationsPersistent postoperative painPre-existing co-morbiditiesPractice advisorySociety of Cardiovascular AnesthesiologistsAnalgesic regimenRespiratory complicationsSignificant painPerioperative providersPain managementCo-morbiditiesNormal respiratory mechanicsPainSide effectsImpaired recoveryRespiratory mechanicsPatientsCardiovascular Anesthesiologists
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply